clinical research and field studies of infectious diseases study section

• Medical Departments & Centers
• Infectious Diseases
• Clinical trials

Below are current clinical trials.

Filter this list of studies by location, status and more.

COVID-19 and Acute Renal Failure

Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Rochester, Minn.

The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI).

A Study of Nervous System Involvement of Coccidioidomycosis at Mayo Clinic Hospital in Arizona

Scottsdale/Phoenix, Ariz.

The purpose of this study is to gain a better understanding of the presentation, diagnostics, disease course and treatment variations, as well as the factors that may influence features of neuro-invasive Coccidioidomycosis. 

Genetic Expression in Osteolysis, Infection, Arthrofibrosis & Metal Reactions in THA & TKA: A Microarray Analysis to Characterize Individual Host Response to the Molecular Mechanisms of Loosening and Arthrofibrosis

Rochester, Minn.

This study is being conducted to determine gene and protein expression profiles (i.e. which genes and proteins are turned off and on) of those with a possibility of developing osteolysis, infection, arthrofibrosis or metallosis of their THA/TKA.

Laboratory Assay Optimization 2.0

The purpose of this study is to better understand the role of HIV and/or HCV infection and/or SARS-CoV-2 on the immune system and potential ways to eliminate the virus(es).

Detection of Infection in Arthroplasty

The purpose of this study is to determine the sensitivity, specificity, positive and negative predictive values of molecular detection of microorganisms, detection of microbial proteins and antibodies against microorganisms, and inflammatory markers (e.g., leukocyte esterase, CRP) in synovial fluid for the diagnosis of prosthetic joint infection (PJI).

NSITE: Novel Strategies to Increase Telehealth Engagement

Eau Claire, Wis., Rochester, Minn.

The primary objective of Aim 1 of this study are to identify personal and social determinant of health-related key factors that present as a barriers to use of non-emergent telehealth care during the COVID-19 pandemic. Aim 1 will use a qualitative study design to understand the experiences of patients along with social determinants of health (SDOH). The results of the qualitative work will be used by the research team to design the survey for administration in Aim 2.

The primary objectgive of Aim 2 of this study is to assess personal and social determinants of health that are associated with patient’s decision to prefer face-to-face visits compared with telehealth appointments for non-emergent care. 

Study Using Clofazimine to Treat Patients with Non-Tuberculous Mycobacterial Infections

The purpose of this study is to determine whether adding clofazimine in a treatment regimen for patients with non-tuberculous mycobacterial (NTM) infections will improve low clinical success rates in NTM infections, its mode of action, and literature reported clinical data in both NTM and multidrug-resistant tuberculosis.

A Study to Assess International SARS-CoV-2 (COVID-19) Infection

T cell response to covid19 vaccinated individuals.

Rochester, Minn., Jacksonville, Fla.

The first aim of this study is to verify that the TCR beta sequencing and curation platforms we will be using are able to identify patients with severe COVID-19 based on the TCR repertoires. This may be accomplished by testing and analyzing results between two cohorts: patients presenting acutely to MCF with mild COVID-19 and patients presenting with severe COVID-19. This will be accomplished by utilizing the the immunoSEQ Human T-cell Receptor Beta (hsTCB) Assay (Adaptive Biothechnologies) and the publicly available ImmuneCODE Open Access Database to confirm previously published data (PMID: 34253751). Both procedures will be performed by the company that created both platforms, Adaptive Biothechnologies.

The second aim of this study is to sequence the TCR receptors of participating patients and identify TCR motifs that may indicate a predisposition to (or protection from) severe SARS-CoV-2, leading to possible risk stratification of such patients, and whether or not age, gender or ethnicity has any contribution to said risk. This may require that we examine all three cohorts listed in the Subject Information section.

The third aim is to measure SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies to distinguish patients that have not been exposed to SARS-CoV-2 to those that have been exposed.

Evaluation of the Effects of Caffeine, Via the ACE2 Receptor, on Clinical Severity of COVID-19 Disease

Jacksonville, Fla.

The purpose of this study is to assess levels of caffeine intake among patients who tested positive for COVID-19 infection and compare that to disease severity.

• Tests & procedures
• Conditions treated
• Specialty groups
• Expertise & rankings
• Patient stories
• Costs & insurance
• News from Mayo Clinic

Research: It's all about patients

[MUSIC PLAYING]

Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight.

• Request an Appointment

5X Challenge

Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.

Division of Infectious Diseases section navigation

Infectious diseases research.

The Division of Infectious Diseases engages in a broad spectrum of basic, clinical, translational, and epidemiologic sciences. The division garners more than $30 million in research funding per year.

Infectious Diseases   faculty collaborate actively with other top-rated local and regional programs, including the   Emory Vaccine Center , the   Emory Department of Microbiology and Immunology , the   Emory Rollins School of Public Health , and the   Centers for Disease Control and Prevention (CDC) , in addition to numerous centers in the United States and abroad.

You can view ongoing trials in Infectious Diseases by visiting Emory Clinical Trials . 

Research Programs

• Antibiotic Resistance Center
• Center for AIDS Research
• Kwazulu-Natal Drug Resistance Surveillance Study
• Emerging Infections Program
• Emory Clinical Trials Unit
• Emory  T32  Training Program in Translational Research to End the HIV Epidemic
• Hope Clinic - Vaccine Research
• Prevention Epicenter of Emory and Collaborating Healthcare Facilities (PEACH)
• Ponce Clinical Research Site
• Infectious Diseases Clinical Research Collaborative
• Integrating HIV and heart health in South Africa (iHEART-SA) project
• Research in HIV and Women's Health and Y This Harmony Matters (RHYTHM)

Basic Science Research Opportunities

Basic scientific research within the Division of Infectious Diseases focuses on:

• Mechanisms and control of antibiotic resistance
• Treatment of hospital-acquired infections, such as  Clostridium difficile  ( C. difficile )
• Pathogenesis of infectious diseases, such as bacterial meningitis
• Basic and translational research in HIV
• Immunology of host defenses and vaccine development

Major areas of investigation of bacterial pathogens include:

• Analysis of virulence mechanisms of invasive bacterial pathogens
• The role of endogenous bacterial CRISPR/Cas9 systems in host immune evasion and targeted DNA editing
• Genomics of bacterial virulence and antibiotic resistance; study of the microbiome
• Studies of the molecular mechanisms of antibiotic resistance
• Research into the role of transposable elements and repetitive nucleotide sequences in microbial pathogenesis and agents associated with bioterrorism
• Metagenomics of pathogens for basic and clinical research

The Division of Infectious Diseases participates in graduate programs and research in   microbiology   and molecular genetics, immunology and molecular pathogenesis, as well as population biology, ecology, and evolution.

Additional opportunities are available for basic science research in:

• Toxin-mediated infections
• Intracellular pathogens
• Hemorrhagic fever viruses
• Zoonotic pathogens
• Parasites and fungi
• Population biology
• Genomics and metagenomics

Emory Vaccine Center and Emory Hope Clinic

The   Emory Vaccine Center   receives more than $24 million in sponsored research funding. Primary program areas in basic science and translational research currently include HIV/AIDS, tuberculosis, malaria, Hepatitis C virus (HCV), cytomegalovirus, gamma-herpes viruses, influenza and DNA and protein-conjugate vaccines.

The Hope Clinic , a unit of the   Emory Vaccine Center   directed by Mark Mulligan, MD, conducts clinical research, vaccine trials and critical research on vaccine policies. A number of additional opportunities for basic scientific research are available in the   Graduate Divisions of Microbiology and Immunology   and through the   Centers for Disease Control .

Clinical and Diagnostic Microbiology

Emory University Hospital   and   Grady Memorial Hospital   have outstanding resources in diagnostic and clinical microbiology.

Areas of focus include:

• Development and assessment of diagnostic tools based on nucleic acid detection
• Optimization of laboratory procedures for diagnosis of mycobacterial infections
• Assessment of the accuracy of automated systems for detection of antimicrobial resistance

Clinical/Translational Research Opportunities and Global Health

Major areas of focus for clinical/translational research in infectious diseases include:

• HIV/AIDS; access to and retention in care
• Sexually transmitted infections
• C. difficile infections; prevention and treatment modalities
• Tuberculosis
• Vaccine research
• Healthcare epidemiology and healthcare infections
• Transplant Infectious Diseases
• Emerging infectious diseases
• Global health
• Bioterrorism

Clinical research training opportunities are enhanced by the presence of Clinical Interaction Sites at the   Emory-affiliated hospitals .

In addition, opportunities for clinical and translational research training are enhanced by the presence of the NIH-funded CTSA award ( Georgia Clinical and Translational Science Alliance , or CTSA) which was awarded to Emory University in collaboration with Morehouse School of Medicine and the Georgia Institute of Technology. A major component of the ACTSI is the Research Education, Training and Career Development program, which includes the Master of Science in Clinical Research (MSCR).

Clinical Infectious Diseases Study Guide

A Problem-Based Approach

• © 2020
• Joseph Domachowske 0 ,
• Manika Suryadevara 1

Department of Pediatrics, SUNY Upstate Medical University, Syracuse, USA

You can also search for this author in PubMed   Google Scholar

• The only study guide that is current on basic infections disease fundamentals
• Written by experts in both adult and pediatric infections
• Each chapter follows a consistent format for ease of use
• Can serve as a standalone book or as a complement to a larger book accompanying a course, such as Introduction to Clinical Infectious Diseases
• The chapters and writing style parallel the larger textbook with an additional 15 topics covered

64k Accesses

2 Citations

5 Altmetric

This is a preview of subscription content, log in via an institution to check access.

Access this book

Subscribe and save.

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime
• Available as EPUB and PDF
• Read on any device
• Instant download
• Own it forever
• Compact, lightweight edition
• Dispatched in 3 to 5 business days
• Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

About this book

Similar content being viewed by others.

Infectious Diseases

Infectious Disease

Person-Centered Infectious Diseases and Pandemics

• Diagnostic microbiology
• Tropical infections of global importance
• Infections of the central nervous system
• Fundamentals of infectious diseases
• Infections of the respiratory tract
• infectious diseases

Table of contents (58 chapters)

Front matter, bacterial infections of skin and skin structures.

Joseph Domachowske, Manika Suryadevara

Febrile Exanthems of Childhood

Acute and chronic lymphadenitis, endophthalmitis, otitis, sinusitis, and mastoiditis, pharyngitis and pharyngeal space infections, pertussis and pertussis syndrome, laryngitis, tracheitis, epiglottitis, and bronchiolitis, community-acquired pneumonia, influenza infection, tuberculosis, atypical pneumonia, fungal pneumonia, infective endocarditis, infectious myocarditis, acute rheumatic fever, kawasaki disease, infectious hepatitis, authors and affiliations, about the authors, bibliographic information.

Book Title : Clinical Infectious Diseases Study Guide

Book Subtitle : A Problem-Based Approach

Authors : Joseph Domachowske, Manika Suryadevara

DOI : https://doi.org/10.1007/978-3-030-50873-9

Publisher : Springer Cham

eBook Packages : Medicine , Medicine (R0)

Copyright Information : The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2020

Softcover ISBN : 978-3-030-50872-2 Published: 06 August 2020

eBook ISBN : 978-3-030-50873-9 Published: 05 August 2020

Edition Number : 1

Number of Pages : IX, 380

Number of Illustrations : 27 b/w illustrations, 32 illustrations in colour

Topics : Infectious Diseases , Medical Microbiology , General Practice / Family Medicine , Pediatrics

• Publish with us

Policies and ethics

• Find a journal
• Track your research

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• Review Article
• Published: 14 February 2020

A systems approach to infectious disease

• Manon Eckhardt 1 , 2 , 3   na1 ,
• Judd F. Hultquist 1 , 2 , 3 , 4   na1 ,
• Robyn M. Kaake 1 , 2 , 3 ,
• Ruth Hüttenhain 1 , 2 , 3 &
• Nevan J. Krogan   ORCID: orcid.org/0000-0003-4902-337X 1 , 2 , 3  

Nature Reviews Genetics volume  21 ,  pages 339–354 ( 2020 ) Cite this article

10k Accesses

70 Citations

85 Altmetric

Metrics details

• Gene regulatory networks
• Infectious diseases
• Regulatory networks
• Systems biology

Ongoing social, political and ecological changes in the 21st century have placed more people at risk of life-threatening acute and chronic infections than ever before. The development of new diagnostic, prophylactic, therapeutic and curative strategies is critical to address this burden but is predicated on a detailed understanding of the immensely complex relationship between pathogens and their hosts. Traditional, reductionist approaches to investigate this dynamic often lack the scale and/or scope to faithfully model the dual and co-dependent nature of this relationship, limiting the success of translational efforts. With recent advances in large-scale, quantitative omics methods as well as in integrative analytical strategies, systems biology approaches for the study of infectious disease are quickly forming a new paradigm for how we understand and model host–pathogen relationships for translational applications. Here, we delineate a framework for a systems biology approach to infectious disease in three parts: discovery — the design, collection and analysis of omics data; representation — the iterative modelling, integration and visualization of complex data sets; and application — the interpretation and hypothesis-based inquiry towards translational outcomes.

This is a preview of subscription content, access via your institution

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

24,99 € / 30 days

cancel any time

Subscribe to this journal

Receive 12 print issues and online access

176,64 € per year

only 14,72 € per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Modelling microbial infection to address global health challenges

A compendium of multi-omics data illuminating host responses to lethal human virus infections

Host genetics and infectious disease: new tools, insights and translational opportunities

World Health Organization. WHO global health estimates 2016: disease burden by cause, age, sex, by country and by region, 2000–2016 (WHO, 2018).

Aderem, A. et al. A systems biology approach to infectious disease research: innovating the pathogen-host research paradigm. mBio 2 , e00325–e00410 (2011).

Article   PubMed   PubMed Central   Google Scholar  

Hillmer, R. A. Systems biology for biologists. PLoS Pathog. 11 , e1004786 (2015). An approachable introduction to systems biology for experimentalists .

Article   PubMed   PubMed Central   CAS   Google Scholar  

Kitano, H. Systems biology: a brief overview. Science 295 , 1662–1664 (2002). A foundational introduction to the principles of systems biology .

Article   CAS   PubMed   Google Scholar  

Ideker, T., Galitski, T. & Hood, L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2 , 343–372 (2001).

Casadevall, A. & Pirofski, L. A. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect. Immun. 67 , 3703–3713 (1999).

Article   CAS   PubMed   PubMed Central   Google Scholar  

Fischbach, M. A. & Krogan, N. J. The next frontier of systems biology: higher-order and interspecies interactions. Genome Biol. 11 , 208 (2010).

[No authors listed] Pathogenesis: of host and pathogen. Nat. Immunol . 7 , 217 (2006).

Westerhoff, H. V. & Palsson, B. O. The evolution of molecular biology into systems biology. Nat. Biotechnol. 22 , 1249–1252 (2004).

Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. Genome Biol. 18 , 83 (2017).

Vidova, V. & Spacil, Z. A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. Anal. Chim. Acta 964 , 7–23 (2017).

Aebersold, R. & Mann, M. Mass-spectrometric exploration of proteome structure and function. Nature 537 , 347–355 (2016).

Bensimon, A., Heck, A. J. & Aebersold, R. Mass spectrometry-based proteomics and network biology. Annu. Rev. Biochem. 81 , 379–405 (2012).

Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet. 20 , 207–220 (2019).

Rinschen, M. M., Ivanisevic, J., Giera, M. & Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. Nat. Rev. Mol. Cell Biol. 20 , 353–367 (2019).

Doench, J. G. Am I ready for CRISPR? A user’s guide to genetic screens. Nat. Rev. Genet. 19 , 67–80 (2018).

Johnson, C. H., Ivanisevic, J. & Siuzdak, G. Metabolomics: beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell Biol. 17 , 451–459 (2016).

Needham, E. J., Parker, B. L., Burykin, T., James, D. E. & Humphrey, S. J. Illuminating the dark phosphoproteome. Sci. Signal. 12 , eaau8645 (2019).

Saliba, A. E., Vonkova, I. & Gavin, A. C. The systematic analysis of protein-lipid interactions comes of age. Nat. Rev. Mol. Cell Biol. 16 , 753–761 (2015).

Wang, D. & Bodovitz, S. Single cell analysis: the new frontier in ‘omics’. Trends Biotechnol. 28 , 281–290 (2010).

Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17 , 333–351 (2016).

Ideker, T. & Krogan, N. J. Differential network biology. Mol. Syst. Biol. 8 , 565 (2012).

Greco, T. M. & Cristea, I. M. Proteomics tracing the footsteps of infectious disease. Mol. Cell Proteom. 16 , S5–S14 (2017).

Article   Google Scholar  

Jean Beltran, P. M., Federspiel, J. D., Sheng, X. & Cristea, I. M. Proteomics and integrative omic approaches for understanding host-pathogen interactions and infectious diseases. Mol. Syst. Biol. 13 , 922 (2017).

Oxford, K. L. et al. The landscape of viral proteomics and its potential to impact human health. Expert. Rev. Proteomics 13 , 579–591 (2016).

Shah, P. S., Wojcechowskyj, J. A., Eckhardt, M. & Krogan, N. J. Comparative mapping of host-pathogen protein-protein interactions. Curr. Opin. Microbiol. 27 , 62–68 (2015).

Puschnik, A. S., Majzoub, K., Ooi, Y. S. & Carette, J. E. A CRISPR toolbox to study virus-host interactions. Nat. Rev. Microbiol. 15 , 351–364 (2017).

Grubaugh, N. D. et al. Tracking virus outbreaks in the twenty-first century. Nat. Microbiol. 4 , 10–19 (2019).

Houldcroft, C. J., Beale, M. A. & Breuer, J. Clinical and biological insights from viral genome sequencing. Nat. Rev. Microbiol. 15 , 183–192 (2017).

Newsom, S. N. & McCall, L. I. Metabolomics: Eavesdropping on silent conversations between hosts and their unwelcome guests. PLoS Pathog. 14 , e1006926 (2018).

Bernstein, B. E. et al. The NIH roadmap epigenomics mapping consortium. Nat. Biotechnol. 28 , 1045–1048 (2010).

Legrain, P. et al. The human proteome project: current state and future direction. Mol. Cell. Proteomics 10 , M111.009993 (2011).

Lander, E. S. Initial impact of the sequencing of the human genome. Nature 470 , 187–197 (2011).

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat. Methods 5 , 621–628 (2008). Pioneering work demonstrating the use of RNA sequencing to quantify changes in the mammalian transcriptome .

Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 , 431–437 (2004).

Paddison, P. J. et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 428 , 427–431 (2004).

Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343 , 80–84 (2014).

Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343 , 84–87 (2014).

Pan, C., Kumar, C., Bohl, S., Klingmueller, U. & Mann, M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol. Cell. Proteomics 8 , 443–450 (2009).

Sandberg, R. & Ernberg, I. The molecular portrait of in vitro growth by meta-analysis of gene-expression profiles. Genome Biol. 6 , R65 (2005).

Ross, D. T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24 , 227–235 (2000).

Fux, C. A., Shirtliff, M., Stoodley, P. & Costerton, J. W. Can laboratory reference strains mirror “real-world” pathogenesis? Trends Microbiol. 13 , 58–63 (2005).

Jenkins, J. What is the key best practice for collaborating with a computational biologist? Cell Syst. 3 , 7–11 (2016).

Article   CAS   Google Scholar  

Lapatas, V., Stefanidakis, M., Jimenez, R. C., Via, A. & Schneider, M. V. Data integration in biological research: an overview. J. Biol. Res. 22 , 9 (2015).

Google Scholar  

Elde, N. C. et al. Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. Cell 150 , 831–841 (2012).

Rauch, B. J. et al. Inhibition of CRISPR-Cas9 with bacteriophage proteins. Cell 168 , 150–158.e10 (2017).

Weekes, M. P. et al. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157 , 1460–1472 (2014).

Huttenhain, R. et al. ARIH2 is a Vif-dependent regulator of CUL5-mediated APOBEC3G degradation in HIV infection. Cell Host Microbe 26 , 86–99.e7 (2019).

Jean Beltran, P. M., Mathias, R. A. & Cristea, I. M. A portrait of the human organelle proteome in space and time during cytomegalovirus infection. Cell Syst. 3 , 361–373.e6 (2016).

Holgate, S. A. How to collaborate. Science https://www.sciencemag.org/careers/2012/07/how-collaborate (2012).

Du, Y. et al. Genome-wide identification of interferon-sensitive mutations enables influenza vaccine design. Science 359 , 290–296 (2018). A systems analysis of interferon sensitivity in influenza A viruses made possible by the design of new vaccine approaches, with proof of principle in animal models .

Elde, N. C., Child, S. J., Geballe, A. P. & Malik, H. S. Protein kinase R reveals an evolutionary model for defeating viral mimicry. Nature 457 , 485–489 (2009).

Collins, J. et al. Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature 553 , 291–294 (2018).

Carey, A. F. et al. TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities. PLoS Pathog. 14 , e1006939 (2018).

Integrative, H. M. P. R. N. C. The integrative human microbiome project. Nature 569 , 641–648 (2019).

Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 , 367–377 (1996). An early example of population genomics in infectious disease; this is the first report of the Δ32 mutation in human CCR5 conferring natural resistance to HIV-1 infection .

Bryant, J. M. et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 381 , 1551–1560 (2013).

Bengsch, B. et al. Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells. Immunity 48 , 1029–1045.e5 (2018).

Hamdane, N. et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology 156 , 2313–2329.e7 (2019).

Article   PubMed   Google Scholar  

Kennedy, E. M. et al. Posttranscriptional m(6)A editing of HIV-1 mRNAs enhances viral gene expression. Cell Host Microbe 22 , 830 (2017).

Arvey, A. et al. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12 , 233–245 (2012).

Jeng, E. E. et al. Systematic identification of host cell regulators of Legionella pneumophila pathogenesis using a genome-wide CRISPR screen. Cell Host Microbe 26 , 551–563.e6 (2019).

Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530 , 108–112 (2016).

Marceau, C. D. et al. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature 535 , 159–163 (2016).

Hultquist, J. F. et al. A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human T cells. Cell Rep. 17 , 1438–1452 (2016).

Park, R. J. et al. A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors. Nat. Genet. 49 , 193–203 (2017).

Hoffmann, H. H. et al. Diverse viruses require the calcium transporter SPCA1 for maturation and spread. Cell Host Microbe 22 , 460–470.e5 (2017).

Korbee, C. J. et al. Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials. Nat. Commun. 9 , 358 (2018).

Zhou, P. et al. Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose. Nature 561 , 122–126 (2018). A host- and pathogen-based systems approach allows the paired identification of a new bacterial pathogen-associated molecular pattern and its receptor in human cells .

Patrick, K. L. et al. Quantitative yeast genetic interaction profiling of bacterial effector proteins uncovers a role for the human retromer in salmonella infection. Cell Syst. 7 , 323–338 e326 (2018).

Ramage, H. R. et al. A combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decay. Mol. Cell 57 , 329–340 (2015).

Hultquist, J. F. et al. CRISPR-Cas9 genome engineering of primary CD4 + T cells for the interrogation of HIV-host factor interactions. Nat. Protoc. 14 , 1–27 (2019).

Brass, A. L. et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319 , 921–926 (2008). A pioneering, RNA interference-based, functional genomics screen for the identification of host factors required for HIV-1 replication in human cells .

Michlmayr, D. et al. Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases. Mol. Syst. Biol. 14 , e7862 (2018).

Thompson, E. G. et al. Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis 107 , 48–58 (2017).

Sychev, Z. E. et al. Integrated systems biology analysis of KSHV latent infection reveals viral induction and reliance on peroxisome mediated lipid metabolism. PLoS Pathog. 13 , e1006256 (2017).

Lupberger, J. et al. Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus-infected cells and liver to identify pathways associated with disease development. Gastroenterology 157 , 537–551 e539 (2019).

Bradley, T., Ferrari, G., Haynes, B. F., Margolis, D. M. & Browne, E. P. Single-cell analysis of quiescent HIV infection reveals host transcriptional profiles that regulate proviral latency. Cell Rep. 25 , 107–117.e3 (2018).

Russell, A. B., Trapnell, C. & Bloom, J. D. Extreme heterogeneity of influenza virus infection in single cells. eLife 7 , e32303 (2018).

Diep, J. et al. Enterovirus pathogenesis requires the host methyltransferase SETD3. Nat. Microbiol. 4 , 2523–2537 (2019). A combined functional genomics and proteomics approach allows the identification of a new enterovirus host factor, with validation in primary human cells and translationally focused extension into an animal model .

Shah, P. S. et al. Comparative flavivirus-host protein interaction mapping reveals mechanisms of dengue and zika virus pathogenesis. Cell 175 , 1931–1945.e18 (2018).

Tripathi, S. et al. Meta- and orthogonal integration of influenza “OMICs” data defines a role for UBR4 in virus budding. Cell Host Microbe 18 , 723–735 (2015).

Mirrashidi, K. M. et al. Global mapping of the Inc-human interactome reveals that retromer restricts chlamydia infection. Cell Host Microbe 18 , 109–121 (2015).

Jager, S. et al. Global landscape of HIV-human protein complexes. Nature 481 , 365–370 (2011). A pioneering study systematically identifying the physical interactions of all HIV-1 proteins and polyproteins with host proteins using affinity tagging and purification mass spectrometry .

Penn, B. H. et al. An Mtb-human protein-protein interaction map identifies a switch between host antiviral and antibacterial responses. Mol. Cell 71 , 637–648.e5 (2018).

Davis, Z. H. et al. Global mapping of herpesvirus-host protein complexes reveals a transcription strategy for late genes. Mol. Cell 57 , 349–360 (2015).

Kane, J. R. et al. Lineage-specific viral hijacking of non-canonical E3 ubiquitin ligase cofactors in the evolution of Vif anti-APOBEC3 activity. Cell Rep. 11 , 1236–1250 (2015).

Babu, M. et al. Global landscape of cell envelope protein complexes in Escherichia coli. Nat. Biotechnol. 36 , 103–112 (2018).

Batra, J. et al. Protein interaction mapping identifies RBBP6 as a negative regulator of Ebola virus replication. Cell 175 , 1917–1930.e13 (2018).

Eckhardt, M. et al. Multiple routes to oncogenesis are promoted by the human papillomavirus-host protein network. Cancer Discov. 8 , 1474–1489 (2018).

Zampieri, M. et al. High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. Sci. Transl Med. 10 , eaal3973 (2018). A metabolomics approach to decipher the mechanism of action of small-molecule antimicrobial compounds with translational potential .

Rother, M. et al. Combined human genome-wide RNAi and metabolite analyses identify IMPDH as a host-directed target against chlamydia infection. Cell Host Microbe 23 , 661–671.e8 (2018).

Yuan, S. et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat. Commun. 10 , 120 (2019).

Fontaine, K. A., Sanchez, E. L., Camarda, R. & Lagunoff, M. Dengue virus induces and requires glycolysis for optimal replication. J. Virol. 89 , 2358–2366 (2015).

Article   PubMed   CAS   Google Scholar  

Brazma, A. Minimum information about a microarray experiment (MIAME)–successes, failures, challenges. ScientificWorldJournal 9 , 420–423 (2009).

Barrett, T. et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 41 , D991–D995 (2013).

Bustin, S. A. et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55 , 611–622 (2009).

Kahl, G. in The Dictionary of Genomics, Transcriptomics, and Proteomics (Wiley-VCH, 2015).

Sansone, S. A. et al. FAIRsharing as a community approach to standards, repositories and policies. Nat. Biotechnol. 37 , 358–367 (2019). An updated call for FAIR data sharing practices as a community approach to improving scientific research integrity .

Eisenberg, D., Marcotte, E. M., Xenarios, I. & Yeates, T. O. Protein function in the post-genomic era. Nature 405 , 823–826 (2000).

Ma’ayan, A., Blitzer, R. D. & Iyengar, R. Toward predictive models of mammalian cells. Annu. Rev. Biophys. Biomol. Struct. 34 , 319–349 (2005).

Gosak, M. et al. Network science of biological systems at different scales: a review. Phys. Life Rev. 24 , 118–135 (2018).

Ideker, T. & Nussinov, R. Network approaches and applications in biology. PLoS Comput. Biol. 13 , e1005771 (2017).

Wickham, H. Tidy data. J. Stat. Softw. https://doi.org/10.18637/jss.v059.i10 (2014). A fundamental treatise on the clear organization and management of data in modelling and statistics .

Chavan, S. S., Shaughnessy, J. D. Jr. & Edmondson, R. D. Overview of biological database mapping services for interoperation between different ‘omics’ datasets. Hum. Genomics 5 , 703–708 (2011).

Zhang, Y. et al. Influenza research database: an integrated bioinformatics resource for influenza virus research. Nucleic Acids Res. 45 , D466–D474 (2017).

Robertson, D. L. et al. HIV-1 nomenclature proposal. Science 288 , 55–56 (2000).

Parker, T. G., Tindall, B. J. & Garrity, G. M. International Code of Nomenclature of Prokaryotes. Int. J. Syst. Evol. Microbiol. 69 , S1–S111 (2019).

Kim, M. & Tagkopoulos, I. Data integration and predictive modeling methods for multi-omics datasets. Mol. Omics 14 , 8–25 (2018).

D’Argenio, V. The high-throughput analyses era: are we ready for the data struggle? High Throughput 7 , 8 (2018).

Article   PubMed Central   CAS   Google Scholar  

Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 , 2498–2504 (2003).

Sarajlic, A., Malod-Dognin, N., Yaveroglu, O. N. & Przulj, N. Graphlet-based characterization of directed networks. Sci. Rep. 6 , 35098 (2016).

Hagberg, A. A., Swart, P. & Schult, D. Exploring network structure, dynamics, and function using NetworkX. in Proc. 7th Python Sci. Conf. (2008).

Huang, S., Chaudhary, K. & Garmire, L. X. More is better: recent progress in multi-omics data integration methods. Front. Genet. 8 , 84 (2017).

Tarca, A. L., Carey, V. J., Chen, X. W., Romero, R. & Draghici, S. Machine learning and its applications to biology. PLoS Comput. Biol. 3 , e116 (2007).

Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10 , 1523 (2019).

Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47 , D607–D613 (2019).

Huang, D. W. et al. The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8 , R183 (2007).

Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34 , 267–273 (2003).

Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102 , 15545–15550 (2005). The first peer-reviewed report of enrichment analysis as a supervised approach for the interpretation of large biological data sets .

Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28 , 27–30 (2000).

Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 , 25–29 (2000). The first report of the widely used Gene Ontology classifications for human genes to allow standardized interpretation and supervised analysis of genetic data sets .

Foulger, R. E. et al. Representing virus-host interactions and other multi-organism processes in the gene ontology. BMC Microbiol. 15 , 146 (2015).

The Gene Ontology Consortium. The gene ontology resource: 20 years and still going strong. Nucleic Acids Res. 47 , D330–D338 (2019).

Kavvas, E. S. et al. Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance. Nat. Commun. 9 , 4306 (2018).

Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10 , 1108–1115 (2013).

Leiserson, M. D. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47 , 106–114 (2015).

Cotto, K. C. et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 46 , D1068–D1073 (2018).

Li, Y. H. et al. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res. 46 , D1121–D1127 (2018).

Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46 , D1074–D1082 (2018).

Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92 , 414–417 (2012).

Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45 , D945–D954 (2017).

Janes, J. et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc. Natl Acad. Sci. USA 115 , 10750–10755 (2018).

Miller, C. H., Nisa, S., Dempsey, S., Jack, C. & O’Toole, R. Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. Antimicrob. Agents Chemother. 53 , 5279–5283 (2009).

Couture, J. L., Blake, R. E., McDonald, G. & Ward, C. L. A funder-imposed data publication requirement seldom inspired data sharing. PLoS One 13 , e0199789 (2018).

Alsheikh-Ali, A. A., Qureshi, W., Al-Mallah, M. H. & Ioannidis, J. P. Public availability of published research data in high-impact journals. PLoS One 6 , e24357 (2011).

Vines, T. H. et al. The availability of research data declines rapidly with article age. Curr. Biol. 24 , 94–97 (2014).

Savage, C. J. & Vickers, A. J. Empirical study of data sharing by authors publishing in PLoS journals. PLoS One 4 , e7078 (2009).

Wilkinson, M. D. et al. The FAIR guiding principles for scientific data management and stewardship. Sci. Data 3 , 160018 (2016).

Goncalves, R. S. & Musen, M. A. The variable quality of metadata about biological samples used in biomedical experiments. Sci. Data 6 , 190021 (2019).

Chelliah, V. et al. BioModels: ten-year anniversary. Nucleic Acids Res. 43 , D542–D548 (2015).

Juty, N. et al. BioModels: content, features, functionality, and use. CPT Pharmacomet. Syst. Pharmacol. 4 , e3 (2015).

Pillich, R. T., Chen, J., Rynkov, V., Welker, D. & Pratt, D. NDEx: a community resource for sharing and publishing of biological networks. Methods Mol. Biol. 1558 , 271–301 (2017).

Barrett, T. et al. BioProject and BioSample databases at NCBI: facilitating capture and organization of metadata. Nucleic Acids Res. 40 , D57–D63 (2012).

Courtot, M. et al. BioSamples database: an updated sample metadata hub. Nucleic Acids Res. 47 , D1172–D1178 (2019).

Download references

Acknowledgements

J.F.H. is supported by amfAR grant 109504-61-RKRL with funds raised by generationCURE, the Gilead Sciences Research Scholars Program in HIV, US National Institutes of Health (NIH) grant K22 AI136691, a supplement from the NIH-supported Third Coast Center for AIDS Research (P30 AI117943) and a supplement from the NIH-sponsored HARC Center (P50 AI150476). R.M.K. is supported by the NIH-sponsored HARC Center (P50 AI150476) and the NIH-sponsored Host-Pathogen Mapping Initiative (U19 AI135990). R.H. is supported by the US Department of Defense Advanced Research Projects Agency (HR0011-19-2-0020). N.J.K. is supported by the NIH-sponsored HARC Center (P50 AI150476), the NIH-sponsored Host-Pathogen Mapping Initiative (U19 AI135990), the NIH-sponsored FluOMICs consortium (U19 AI135972) and NIH grant P01 AI063302.

Author information

These authors contributed equally: Manon Eckhardt, Judd F. Hultquist.

Authors and Affiliations

Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA

Manon Eckhardt, Judd F. Hultquist, Robyn M. Kaake, Ruth Hüttenhain & Nevan J. Krogan

Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA, USA

J. David Gladstone Institutes, San Francisco, CA, USA

Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Judd F. Hultquist

You can also search for this author in PubMed   Google Scholar

Contributions

M.E., J.F.H, R.M.K. and R.H. researched the literature. M.E., J.F.H, R.M.K., R.H. and N.J.K. wrote the article, provided substantial contributions to discussions of the content and reviewed and/or edited the manuscript before submission.

Corresponding authors

Correspondence to Judd F. Hultquist or Nevan J. Krogan .

Ethics declarations

Competing interests.

The authors declare no competing interests.

Additional information

Peer review information.

Nature Reviews Genetics thanks T. Baumert and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Related links

FAIRsharing: https://fairsharing.org/

Scientific Data recommended data repositories: https://www.nature.com/sdata/policies/repositories

Types of host models that rely on cells taken directly from living tissue (such as from biopsy material or blood) for growth and maintenance ex vivo.

A genetically distinct strain of a pathogen that has been selected for enhanced fitness ex vivo and for use in laboratory experiments even though it is not found as a major strain in the natural world.

Genetic strains of pathogens isolated directly from patients or clinical samples.

Repeated experiments analysing the same sample with the same instrumentation to measure the variability inherent in the testing protocol.

Repeated experiments analysing different samples that represent the same thing (such as samples collected from different patients with the same disease outcome) to determine the variability in the sample pools.

The influence of one or more unmonitored variables on a system’s components or the relationships between those components that can alter experimental interpretation.

A genetic screening technique wherein a codon or set of codons is randomized to produce all possible amino acids at a position or positions.

Iterative rounds of adaptation and counter-adaptation between a pathogen and its host over evolutionary history as a result of the ability of pathogens to elicit selective pressure on their host populations and vice versa.

A method for the random disruption of gene function by the untargeted insertion of transposable retroelements into a genome.

Information that describes a set of data.

The ratio of infectious agents (such as virions or bacteria) to infection targets (such as cells).

A connection point in a network representing a component of the system.

A connection between nodes in a network representing a relationship between two components.

An approach for identifying over-represented classifications of components by comparing the frequency of a given annotation in a data set with a predefined reference list.

A method of data clustering that aims to partition a set of components into a total of k clusters, wherein each component belongs to the cluster with the nearest mean value.

A statistical procedure often used in the development of predictive models, which describes a data set as a series of uncorrelated variables called ‘principal components’ that account for sources of variability.

A machine learning method related to regression analysis that seeks to identify the separation boundary between clusters of data given predefined clusters in a prelabelled set of input data.

A machine learning method that seeks to cluster and classify data on the basis of similarities and differences extracted from a prelabelled set of input data.

A machine learning algorithm that seeks to cluster and classify data on the basis of the ensemble output of a series of decision trees formulated from a prelabelled set of input data.

A measurement of dependency between two variables that is used in machine learning to determine how much can be assumed about one component on the basis of the observed behaviour of another.

Isolation of a given cell population based on an observed trait or characteristic (such as fluorescence or resistance to a toxic compound).

Rights and permissions

Reprints and permissions

About this article

Cite this article.

Eckhardt, M., Hultquist, J.F., Kaake, R.M. et al. A systems approach to infectious disease. Nat Rev Genet 21 , 339–354 (2020). https://doi.org/10.1038/s41576-020-0212-5

Download citation

Accepted : 08 January 2020

Published : 14 February 2020

Issue Date : June 2020

DOI : https://doi.org/10.1038/s41576-020-0212-5

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

Development and psychometric evaluation of nurse’s intention to care for patients with infectious disease scale: an exploratory sequential mixed method study.

• Esmaeil Hoseinzadeh
• Hamid Sharif-Nia
• Abbas Ebadi

BMC Nursing (2024)

Disease outbreak prediction using natural language processing: a review

• Avneet Singh Gautam

Knowledge and Information Systems (2024)

Next-generation proteomics for quantitative Jumbophage-bacteria interaction mapping

• Andrea Fossati
• Deepto Mozumdar
• Danielle L. Swaney

Nature Communications (2023)

Prioritizing non-communicable diseases in the post-pandemic era based on a comprehensive analysis of the GBD 2019 from 1990 to 2019

• Jianhao Shu
• Weifeng Jin

Scientific Reports (2023)

Structure-function analysis of enterovirus protease 2A in complex with its essential host factor SETD3

• Christine E. Peters
• Ursula Schulze-Gahmen
• Nevan J. Krogan

Nature Communications (2022)

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.

• Search Menu
• Sign in through your institution
• Advance articles
• Editor's Choice
• Supplement Archive
• Cover Archive
• IDSA Guidelines
• IDSA Journals
• The Journal of Infectious Diseases
• Open Forum Infectious Diseases
• Photo Quizzes
• State-of-the-Art Reviews
• Voices of ID
• Author Guidelines
• Open Access
• Why Publish
• IDSA Journals Calls for Papers
• Advertising and Corporate Services
• Advertising
• Journals Career Network
• Reprints and ePrints
• Sponsored Supplements
• Branded Books
• About Clinical Infectious Diseases
• About the Infectious Diseases Society of America
• About the HIV Medicine Association
• IDSA COI Policy
• Editorial Board
• Self-Archiving Policy
• For Reviewers
• For Press Offices
• Journals on Oxford Academic
• Books on Oxford Academic

Editor-In-Chief

Deputy Editors

Associate Editors

Associate Editor/Voices of ID Editor

Associate Editor for Supplements/Methodological and Statistical Editor

Cover Art Editors

Mary Grizzard

Michael Grizzard

Statistical Editors

Ashley L. Buchanan

Steven Cohen

Victor De Gruttola

Farzad Noubary

Histopathology Editors

Jeannette Guarner

Mary Klassen-Fischer

Managing Editor

Katherine Eberenz

[email protected]

Contact for Research Integrity and Publication Ethics Questions

Assistant Managing Editor

Blake Campbell

Supplements Specialist

Special section editors     , in the literature.

Stan Deresinski

Photo Quiz/Arcanum

Anthony Amoroso

David J. Riedel

State-of-the-Art Review Editors

Allan R. Tunkel, MD, PhD, MACP

Tara Vijayan, MD

Past Editors

Reviews of infectious diseases.

Edward H. Kass, 1979-1989 (vols. 1-11)

Sydney M. Finegold, 1990-1991 (vols. 12 and 13)

Clinical Infectious Diseases

Sydney M. Finegold, 1992-1999 (vols. 14-29)

Sherwood L. Gorbach, 2000–2016 (vols. 30–63)

Robert T. Schooley, 2017-2022 (vols. 64-74)

Editorial Advisory Board

Brian K. Agan, Bethesda, Maryland

Jan M. Agosti, Seattle, Washington

Samuel L. Aitken, Houston, Texas

Murat Akova, Ankara, Turkey

Michael L. Alkan, Beer Sheva, Israel

David R. Andes, Madison, Wisconsin

Jason R. Andrews, Stanford, California

Spinello Antinori, Milan, Italy

Anucha Apisarnthanarak, Praumthani, Thailand

Ricardo Araujo, Porto, Portugal

Robert D. Arbeit, Boston, Massachusetts

Alejandro Arenas-Pinto, London, United Kingdom

Cesar A. Arias, Houston, Texas

Wendy Armstrong, Atlanta, Georgia

Michael H. Augenbraun, Brooklyn, New York

Paul G. Auwaerter, Baltimore, Maryland

Ritu Banerjee, Nashville, Tennessee

Stephen G. Baum, Bronx, New York

Arnold S. Bayer, Los Angeles, California

Roger J. Bedimo, Dallas, Texas

Robert Belknap, Denver, Colorado

Shalom Ben-Shimol, Beer Sheva, Israel

Jonathan Berman, North Bethesda, Maryland

Gregory P. Bisson, Philadelphia, Pennsylvania

Robert A. Bonomo, Cleveland, Ohio

Louis Bont, Utrecht, Netherlands

Marc J.M. Bonten, Utrecht, Netherlands

Helen W. Boucher, Boston, Massachusetts

David R. Boulware, Minneapolis, Minnesota

William R. Bowie, Vancouver, Canada

Heather Bradley, Atlanta, Georgia

Jared Bullard, Winnipeg, Canada

Steven D. Burdette, Dayton, Ohio

Karen Bush, Bloomington, Indiana

Thomas Butler, Miramar, Florida

André Cabié, Fort-de-France, Martinique

John M. Cafardi, Cincinnati, Ohio

Thomas B. Campbell, Aurora, Colorado

Ann Chahroudi, Atlanta, Georgia

Christina C. Chang, Melbourne, Australia

James D. Cherry, Los Angeles, California

Cheng-Hsun Chiu, Taoyuan, Taiwan

Cornelius J. Clancy, Pittsburgh, Pennsylvania

David B. Clifford, St. Louis, Missouri

Cheryl Cohen, Johannesburg, South Africa

Jonathan A. Colasanti, Atlanta, Georgia

Brian Conway, Vancouver, Canada

Benjamin J. Cowling, Pokfulam, Hong Kong

Ron Dagan, Beer Sheva, Israel

Nick Daneman, Toronto, Canada

Anindita Das, Canberra, Australia

Michael Z. David, Philadelphia, Pennsylvania

Annabelle de St. Maurice, Los Angeles, California

Sarah B. Doernberg, San Francisco, California

Yohei Doi, Pittsburgh, Pennsylvania

Pere Domingo, Barcelona, Spain

Curtis J. Donskey, Cleveland, Ohio

Kelly E. Dooley, Baltimore, Maryland

Robert A. Duncan, Burlington, Massachusetts

Michael W. Dunne, Old Saybrook, Connecticut

John R. Dyer, Perth, Australia

Dean D. Erdman, Atlanta, Georgia

Shelley N. Facente, San Francisco, California

Daniel S. Fierer, New York, New York

William A. Fischer, II, Chapel Hill, North Carolina

Jay A. Fishman, Boston, Massachusetts

Courtney V. Fletcher, Omaha, Nebraska

Anthony R. Flores, Houston, Texas

Nathan Ford, Geneva, Switzerland

Henry S. Fraimow, Camden, New Jersey

Lawrence D. Frenkel, Rockford, Illinois

Alicia M. Fry, Atlanta, Georgia

Luis Furuya-Kanamori, Acton, Australia

Monica Gandhi, San Francisco, California

Jose M. Gatell, Barcelona, Spain

Dale N. Gerding, Hines, Illinois

Sara Gianella Weibel, San Diego, California

Peter H. Gilligan, Chapel Hill, North Carolina

Matthew B. Goetz, Los Angeles, California

Dan M. Granoff, San Francisco, California

David E. Griffith, Tyler, Texas

Carlos G. Grijalva, Nashville, Tennessee

Giovanni Guaraldi, Modena, Italy

Huldrych F. Günthard, Zurich, Switzerland

Colleen Hadigan, Bethesda, Maryland

W. David Hardy, Los Angeles, California

Anthony D. Harris, Baltimore, Maryland

Patrick N.A. Harris, Brisbane, Australia

Rodrigo Hasbun, Houston, Texas

Frederick G. Hayden, Charlottesville, Virginia

Hans H. Hirsch, Basel, Switzerland

Thomas L. Holland, Durham, North Carolina

Edward W. Hook, Birmingham, Alabama

Leigh M. Howard, Nashville, Tennessee

Noreen A. Hynes, Baltimore, Maryland

Michael G. Ison, Chicago, Illinois

Ilesh Jani, Marracuene, Mozambique

Jorgen S. Jensen, Copenhagen, Denmark

Somchai Jongwutiwes, Bangkok, Thailand

Andre C. Kalil, Omaha, Nebraska

Mini Kamboj, New York, New York

Sheldon L. Kaplan, Houston, Texas

Adolf W. Karchmer, Boston, Massachusetts

Carol A. Kauffman, Ann Arbor, Michigan

Colleen F. Kelley, Atlanta, Georgia

James D. Kellner, Calgary, Canada

Brendan J. Kelly, Philadelphia, Pennsylvania

Jeffrey D. Klausner, Los Angeles, California

Keith P. Klugman, Seattle, Washington

Janak Koirala, Springfield, Illinois

Marin H. Kollef, St. Louis, Missouri

Dennis L. Kolson, Philadelphia, Pennsylvania

Shyam Kottilil, Baltimore, Maryland

Peter J. Krause, New Haven, Connecticut

Vincent Le Moing, Montpellier, France

William M. Lee, Dallas, Texas

Jeffrey L. Lennox, Atlanta, Georgia

Emil Lesho, Rochester, New York

Benjamin P. Linas, Boston, Massachusetts

Daniel J. Livorsi, Iowa City, Iowa

Per Ljungman, Stockholm, Sweden

Lisa E. Manhart, Seattle, Washington

Jennifer Manne-Goehler, Boston, Massachusetts

Vincent Marconi, Atlanta, Georgia

Christina M. Marra, Seattle, Washington

Jeanne M. Marrazzo, Birmingham, Alabama

Marianne Martinello, Sydney, Australia

Esteban Martinez, Barcelona, Spain

Henry Masur, Bethesda, Maryland

Kate McCarthy, Brisbane, Australia

Malkanthie I. McCormick, Lexington, Kentucky

Kenneth McIntosh, Boston, Massachusetts

Graeme Meintjes, Cape Town, South Africa

Jean Menotti, Lyon, France

Lynne M. Mofenson, Washington, District of Columbia

Brian T. Montague, Aurora, Colorado

Arnold S. Monto, Ann Arbor, Michigan

David R. Murdoch, Christchurch, New Zealand

Landon Myer, Cape Town, South Africa

Jean B. Nachega, Pittsburgh, Pennsylvania

Kathleen M. Neuzil, Baltimore, Maryland

Valerie L. Ng, Oakland, California

Lindsay E. Nicolle, Winnipeg, Canada

Ran Nir-Paz, Jerusalem, Israel

Amanda Noska, Duluth, Minnesota

Marina Nunez, Winston-Salem, North Carolina

Joseph G. Pastorek, Slidell, Louisiana

Mical Paul, Haifa, Israel

Christopher Payan, Brest, France

Ville Peltola, Turku, Finland

Juan M. Pericas, Barcelona, Spain

Joshua G. Petrie, Ann Arbor, Michigan

Pedro A. Piedra, Houston, Texas

Dylan Pillai, Calgary, Canada

Mathias W. Pletz, Jena, Germany

Raymund R. Razonable, Rochester, Minnesota

Randall R. Reves, Denver, Colorado

John H. Rex, Wellesley, Massachusetts

Frank S. Rhame, Minneapolis, Minnesota

Jurgen K. Rockstroh, Bonn, Germany

William R. Rodriguez, Boston, Massachusetts

Jesús Rodríguez-Baño, Sevilla, Spain

Keith A. Rodvold, Chicago, Illinois

Benjamin A. Rogers, Clayton, Australia

Stephen J. Rogerson, Parkville, Australia

Sarah E. Rowan, Denver, Colorado

Michael S. Saag, Birmingham, Alabama

Lisa Saiman, New York, New York

Max Salfinger, Tampa, Florida

Michael J. Satlin, New York, New York

Mark R. Schleiss, Minneapolis, Minnesota

Audrey N. Schuetz, Rochester, Minnesota

Jennifer E. Schuster, Kansas City, Missouri

John Scott, Seattle, Washington

Edward J. Septimus, Boston, Massachusetts

Irini Sereti, Bethesda, Maryland

Samuel Shelburne, Houston, Texas

Oguz Resat Sipahi, Izmir, Turkey

Graham M. Snyder, Pittsburgh, Pennsylvania

Andrej Spec, St. Louis, Missouri

Brad Spellberg, Los Angeles, California

Sandra A. Springer, New Haven, Connecticut

Serena S. Spudich, New Haven, Connecticut

Jack T. Stapleton, Iowa City, Iowa

Gina A. Suh, Rochester, Minnesota

Mark S. Sulkowski, Baltimore, Maryland

Andrew H. Talal, Buffalo, New York

Paul A. Tambyah, Singapore

Pierre Tattevin, Rennes, France

Elitza Theel, Rochester, Minnesota

Chloe L. Thio, Baltimore, Maryland

David L. Thomas, Baltimore, Maryland

George R. Thompson, Davis, California

Hidenori Toyoda, Ogaki, Japan

Barbara W. Trautner, Houston, Texas

Ephraim L. Tsalik, Durham, North Carolina

Susan Tuddenham, Baltimore, Maryland

Reinout van Crevel, Nijmegen, Netherlands

David van Duin, Chapel Hill, North Carolina

Fernando Vazquez, Oviedo, Spain

Pauline Vetter, Geneva, Switzerland

David H. Walker, Galveston, Texas

Xiu-Feng Wan, Columbia, Missouri

Richard R. Watkins, Akron, Ohio

A. Clinton White, Galveston, Texas

Mark H. Wilcox, Leeds, United Kingdom

Darcy A. Wooten, San Diego, California

Hugh Wright, Brisbane, Australia

Kwok-Yung Yuen, Hong Kong Special Administrative Region, China

Werner Zimmerli, Liestal, Switzerland

• Recommend to your Library

Affiliations

• Online ISSN 1537-6591
• Print ISSN 1058-4838
• Copyright © 2024 Infectious Diseases Society of America
• About Oxford Academic
• Publish journals with us
• University press partners
• What we publish
• New features  
• Open access
• Institutional account management
• Rights and permissions
• Get help with access
• Accessibility
• Media enquiries
• Oxford University Press
• Oxford Languages
• University of Oxford

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide

• Copyright © 2024 Oxford University Press
• Cookie settings
• Cookie policy
• Privacy policy
• Legal notice

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

• Latest CDC Covid-19 Info
• CSR Extranet
• Staff Directory
• Contact CSR

For Applicants

CSR’s primary role is to handle the receipt and review of ~ 75% of the grant applications that NIH receives. NIH separates the review process from funding decisions.

For Reviewers

Reviewers are critical to our mission to see that NIH grant applications receive, fair, independent, expert, and timely scientific reviews. We appreciate the generosity with which reviewers give their time.

News & Policy

The latest news and policy updates from CSR. Read about our outreach programs and publications.

• Study Sections

Applications are reviewed in study sections (Scientific Review Group, SRG). Review Branches (RBs) are clusters of study sections based on scientific discipline.

Review Panels & Dates

Evaluating panel quality in review (enquire), enquire overview.

• Cluster Overview Process

Clusters Evaluated via ENQUIRE

ENQUIRE Overview Cluster Overview Process Clusters Evaluated via ENQUIRE

Science changes rapidly. Making sure that study sections change with the science is an ongoing challenge. CSR ENQUIRE integrates data and input from multiple stakeholders to determine whether changes in study section focus or scope are needed to facilitate the identification of high impact science, with special consideration of emerging science.

Words from Dr. Noni Byrnes, CSR Director

Science-based Clusters of study sections are formed based on scientific topics (instead of CSR managerial units) for review via ENQUIRE

Systematic, data-driven, continuous process ~20% of CSR study sections are evaluated each year, every study section evaluated every 5 years

Stakeholder input and involvement External scientific community, extramural programs at NIH, CSR staff

Iterative Approach Continuous refinement of the process based on experience

Critical to success Matching referral of applications and reviewer expertise to redefined scientific scope of study sections

Multiple Possible Actions Follow

• Change in scientific guidelines
• Merge study sections
• Create new study sections
• Redistribute areas across study sections
• Add emerging areas of science
• Eliminate study sections

• current scientific guidelines
• sample abstracts & aims
• data on workload trends, bibliometric output, ESI submission and success rates

• workload data
• scoring trends
• survey feedback from reviewers & program officers
• site-visit information on meeting function
• External Scientific Working Group’s report

• CSR Advisory Council
• NIH Office of the Director

• Test practicality of new guidelines through mock application referral
• Reassignment of standing study section members to fit guidelines of new study sections
• Publicize new study sections to the community
• Monitor referral & adherence to new guidelines

Brain Disorders: Clinical, Translational, and Neurotechnology

Immunology and respiratory systems, drug synthesis, discovery, disposition, and xenobiotics, microbiology and infectious diseases, epidemiology and population sciences, molecular and cellular basic sciences, healthcare delivery/patient outcomes, gi, renal, endocrine systems, cardiac, vascular and hematologic sciences, functional/cognitive neuroscience, clusters evaluated via enquire in 2023, study sections evaluated (12).

• Acute Neural Injury and Epilepsy ANIE
• Adult Psychopathology and Disorders of Aging APDA
• Aging Systems and Geriatric Study Section ASG
• Bioengineering of Neuroscience, Vision Technologies BNVT
• Clinical Neuroimmunology and Brain Tumors CNBT
• Clinical Neuroscience and Neurodegeneration CNN
• Child Psychopathology and Developmental Disabilities CPDD
• Developmental Brain Disorders DBD
• Emerging Imaging Technologies in Neuroscience EITN
• Neural Basis of Psychopathology, Addictions, and Sleep Disorders NPAS
• Noninvasive Neuromodulation and Neuroimaging Technologies ETTN 91
• Vision Imaging, Bioengineering, and Low Vision Technology Development ETTN 81 (BIVT)

Resulting Study Sections (14)

• Adult Lifespan Psychopathology ALP
• Brain Injury and Neurovascular Disorders BIND
• Bioengineering and Tissue Engineering for Neuroscience BTEN
• Cognitive Disorders and Brain Aging CDBA
• Clinical Neurodegeneration Translational Neuroscience CNTN
• Imaging and Bioengineering Technology for Visual Systems (recurring SEP) IBV
• Imaging Technologies in Neuroscience ITN
• Neuro Informatic, Computational and Data Analysis (recurring SEP) NICD
• Neuromodulation and Imaging of Neuronal Circuits NINC

Study Sections Evaluated (10)

• Arthritis, Connective Tissue and Skin ACTS
• Cellular and Molecular Immunology A CMIA
• Cellular and Molecular Immunology B CMIB
• Hypersensitivity, Autoimmune, and Immune-mediated Diseases HAI
• Hypersensitivity, Allergies and Mucosal Immunology IIDB (57)
• Innate Immunity and Inflammation III
• Lung Cellular, Molecular, and Immunobiology LCMI
• Lung Injury, Repair, and Remodeling LIRR
• Respiratory Integrative Biology and Translational Research RIBT
• Transplantation, Tolerance and Tumor Immunology TTT

Resulting Study Sections (12)

• Adaptive Immunity AI
• Innate Immunity A ZRG1 IIDA (81)
• Innate Immunity B IIB
• Immune Mechanisms of Hypersensitivity and Allergy IMHA
• Immunobiology of Transplantation and Alloimmunity ITA
• Lung Immunology and Infection LII
• Mechanisms of Autoimmunity MAI
• Molecular and Structural Immunology MSI
• Pulmonary Injury Remodeling and Repair PIRR
• Pulmonary Vascular Disease and Physiology PVP
• Skin and Connective Tissue Sciences SCTS
• Translational Investigations of Pulmonary and Immunological Diseases ZRG1 RCCS (81)

Clusters Evaluated via ENQUIRE in 2022

Study sections evaluated (14).

• Cancer Etiology CE
• Drug Discovery for the Nervous System DDNS
• Drug Discovery and Mechanisms of Antimicrobial Resistance DDR
• Drug Discovery and Molecular Pharmacology DMP
• Developmental Therapeutics DT
• Gene and Drug Delivery Systems GDD
• Nanotechnology NANO
• Synthetic and Biological Chemistry A SBCA
• Synthetic and Biological Chemistry B SBCB
• Systemic Injury by Environmental Exposure SIEE
• Xenobiotic and Nutrient Disposition and Action XNDA
• Topics in Bacterial Pathogenesis ZRG1 AIDC (82)
• Eukaryotic Pathogen Drug Discovery and Resistance ZRG1 AIDC (83)
• PAR Panel: High Throughput Screening ZRG1 BST-F (55)
• Anti-Infective Resistance and Targets AIRT
• Advancing Therapeutics A ATA
• Advancing Therapeutics ZRG1 MCST (81)
• Chemical Biology & Probes CBP
• Chemical Synthesis & Biosynthesis CSB
• Drug and Biologic Disposition and Toxicity DBDT
• Drug and Biologic Therapeutic Delivery DBTD
• Drug Discovery and Molecular Pharmacology A DMPA
• Drug Discovery and Molecular Pharmacology DCAI (81)
• Drug Discovery and Molecular Pharmacology C DMPC
• Drug Discovery and Molecular Pharmacology B DMPB
• Environmental Determinants of Disease EDD
• Innovations in Nanosystems and Nanotechnology INN
• Nucleic Acid Therapeutic Delivery BBBT (81)
• Bacterial Pathogenesis BACP
• Host Interactions with Bacterial Pathogens HIBP
• Immunity and Host Defense IHD
• Prokaryotic Cell and Molecular Biology PCMB
• Pathogenic Eukaryotes PTHE
• Vector Biology VB
• Vaccines Against Microbial Diseases VMD
• Virology - A VIRA
• Virology - B VIRB
• Topics in Bacterial Pathogenesis ZRG1 IIDA-B 80

Resulting Study Sections (11)

• Bacterial-Host Interactions BHI
• Bacterial Virulence BV
• Interspecies Microbial Interactions and Infections IMII
• Molecular and Cellular Biology of Virus Infection MCV
• Transmission of Vector-Borne and Zoonotic Diseases TVZ
• Viral Dynamics and Transmission VDT
• Vaccines Against Microbial Diseases VID
• Viral Pathogenesis and Immunity VPI

Study Sections Evaluated (9)

• Behavioral Genetics and Epidemiology BGES
• Biostatistical Methods and Research Design BMRD
• Cancer, Heart, and Sleep Epidemiology Panel A CHSA
• Cancer, Heart, and Sleep Epidemiology Panel B CHSB
• Clinical Research and Field Studies of Infectious Diseases CRFS
• Genetics of Health and Disease GHD
• Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions IRAP
• Kidney, Nutrition, Obesity and Diabetes KNOD
• Neurological, Aging and Musculoskeletal Epidemiology NAME

Resulting Study Sections (13)

• Aging, Injury, Musculoskeletal, and Rheumatologic Disorders AIMR
• Analytics and Statistics for Population Research Panel A ASPA
• Analytics and Statistics for Population Research Panel B ASPB
• Cancer and Hematologic Disorders CHD
• Cardiovascular and Respiratory Diseases CRD
• Etiology, Diagnostic, Intervention and Treatment of Infectious Diseases EDIT
• Kidney, Endocrine, and Digestive Disorders KEDD
• Lifestyle and Health Behaviors LHB
• Neurological, Mental and Behavioral Health NMBH
• Population-based Research in Infectious Disease PRID
• Reproductive, Perinatal, and Pediatric Health RPPH
• Social and Environmental Determinants of Health SEDH
• Cancer Molecular Pathobiology CAMP
• Cancer Biomarkers CBSS
• Cancer Immunopathology and Immunotherapy CII
• Clinical Oncology CONC
• Mechanisms of Cancer Therapeutics - 1 MCT1
• Mechanisms of Cancer Therapeutics - 2 MCT2
• Molecular Oncogenesis MONC
• Tumor Cell Biology TCB
• Tumor Microenvironment TME
• Tumor Progression and Metastasis TPM
• Biochemical and Cellular Oncogenesis BCO
• Cancer Cell Biology CCB
• Cellular Immunotherapy of Cancer CIC
• Gene Regulation in Cancer GRIC
• Molecular Cancer Diagnosis and Classification MCDC
• Mechanisms of Cancer Therapeutics A MCTA
• Mechanisms of Cancer Therapeutics B MCTB
• Mechanisms of Cancer Therapeutics C MCTC
• Tumor Evolution, Heterogeneity and Metastasis TEHM
• Tumor Host Interactions THI
• Translational Immuno-oncology TIO
• Therapeutic Immune Regulation TIR

Clusters Evaluated via ENQUIRE in 2021

Study sections evaluated (16).

• Biochemistry and Biophysics of Membranes BBM
• Biophysics of Neural Systems BPNS
• Cellular Signaling and Regulatory Systems CSRS
• Membrane Biology and Protein Processing MBPP
• Molecular Genetics A MGA
• Molecular Genetics B MGB
• Molecular and Integrative Signal Transduction MIST
• Molecular Neuropharmacology and Signaling MNPS
• Macromolecular Structure and Function A MSFA
• Macromolecular Structure and Function B MSFB
• Macromolecular Structure and Function C MSFC
• Macromolecular Structure and Function D MSFD
• Nuclear and Cytoplasmic Structure/Function and Dynamics NCSD
• Neurotransporters, Receptors, and Calcium Signaling NTRC
• Synapses, Cytoskeleton and Trafficking SYN
• Cell Structure and Function-1 CSF-1
• Cell Structure and Function-2 CSF-2
• Molecular Cellular Neuropharmacology MCNP
• Molecular Genetics MG
• Neuronal Communications NC
• Receptor Biology and Signal Transduction RBST

Clusters Evaluated via ENQUIRE in 2019

• Biomedical Computing and Health Informatics BCHI
• Behavioral Medicine: Interventions and Outcomes BMIO
• Community-Level Health Promotion CLHP
• Clinical Management of Patients in Community-based Settings CMPC
• Dissemination and Implementation Research in Health DIRH
• Health Disparities and Equity Promotion HDEP
• Health Services Organization and Delivery HSOD
• Nursing and Related Clinical Sciences NRCS
• Psychosocial Risk and Disease Prevention PRDP
• Biobehavioral Medicine and Health Outcomes BMHO
• Clinical Data Management and Analysis CDMA
• Clinical Informatics and Digital Health CIDH
• Clinical Management in General Health Care Settings CMGC
• Healthcare and Health Disparities HHD
• Health Promotion in Communities HPC
• Health Services: Quality and Effectiveness HSQE
• Interdisciplinary Clinical Care in Specialty Care Settings ICSC
• Lifestyle Change and Behavioral Health LCBH
• Organization and Delivery of Health Services ODHS
• Science of Implementation in Health and Healthcare SIHH

Study Sections Evaluated (11)

• Cellular Aspects of Diabetes and Obesity CADO
• Clinical and Integrative Diabetes and Obesity CIDO
• Clinical, Integrative and Molecular Gastroenterology CIMG
• Gastrointestinal Mucosal Pathobiology GMPB
• Hepatobiliary Pathophysiology HBPP
• Integrative Nutrition and Metabolic Processes INMP
• Integrative Physiology of Obesity and Diabetes IPOD
• Kidney Molecular Biology and Genitourinary Organ Development KMBD
• Molecular and Cellular Endocrinology MCE
• Pathobiology of Kidney Disease PBKD
• Urology and Urogynecology ZRG1 DKUS 90

Resulting Study Sections (10)

• Basic Mechanisms of Diabetes and Metabolism BMDM
• Cell Signaling and Molecular Endocrinology CSME
• Digestive System Host Defense, Microbial Interactions and Immune and Inflammatory Disease DHMI
• Digestive and Nutrient Physiology and Diseases DNPD
• Human Studies of Diabetes and Obesity HSDO
• Kidney and Urological Systems Function and Dysfunction KUFD
• Nutrition and Metabolism in Health and Disease NMHD
• Pathophysiology of Obesity and Metabolic Disease POMD
• Atherosclerosis and Inflammation of the Cardiovascular System AICS
• Cardiac Contractility, Hypertrophy, and Failure CCHF
• Clinical and Integrative Cardiovascular Sciences CICS
• Electrical Signaling, Ion Transport, and Arrhythmias ESTA
• Hemostasis and Thrombosis HT
• Hypertension and Microcirculation HM
• Molecular and Cellular Hematology MCH
• Myocardial Ischemia and Metabolism MIM
• Vascular Cell and Molecular Biology VCMB
• Transfusion Medicine Sep ZRG1 VH-D 55

Resulting Study Sections (8)

• Atherosclerosis and Vascular Inflammation AVI
• Basic Biology of Blood, Heart and Vasculature BBHV
• Clinical Integrative Cardiovascular and Hematological Sciences CCHS
• Hemostasis, Thrombosis, Blood Cells and Transfusion HTBT
• Integrative Vascular Physiology and Pathology IVPP
• Integrative Myocardial Physiology/Pathophysiology A MPPA
• Integrative Myocardial Physiology/Pathophysiology B MPPB
• Therapeutic Development and Preclinical Studies TDPS
• Auditory System AUD
• Biology of the Visual System BVS
• Cognition and Perception CP
• Chemosensory Systems CSS
• Diseases and Pathophysiology of the Visual System DPVS
• Neurobiology of Learning and Memory LAM
• Language and Communication LCOM
• Neuroendocrinology, Neuroimmunology, Rhythms and Sleep NNRS
• Sensory Motor Integration SMI
• Mechanisms of Sensory, Perceptual, and Cognitive Processes SPC
• Somatosensory and Pain Systems SPS
• Ocular Surface, Cornea, Anterior Segment Glaucoma, and Refractive Error Special Emphasis Panel ZRG1 BDCN-J 81
• Auditory Systems AUD
• Biology and Development of the Eye BDE
• Behavioral Neuroendocrinology, Neuroimmunology, Rhythms, and Sleep BNRS
• Human Complex Mental Function HCMF
• Learning, Memory and Decision Neuroscience LMDN
• Neuroscience of Basic Visual Processes NBVP
• Neuroscience of Interoception and Chemosensation NIC
• Neurobiology of Pain and Itch NPI
• Pathophysiology of Eye Disease 1 PED1
• Pathophysiology of Eye Disease 2 PED2
• Sensory-Motor Neuroscience SMN

Last updated: 09/29/2023 12:31

• More Social Media from NIH

Switching Role/Affiliation

• Manage Preferences

STUDY SECTION ROSTER INFORMATION

Clinical Program Leader

About the role.

Your responsibilities will include but are not limited to: • Acts as a clinical leader responsible for assigned global clinical program(s) -driving medical strategy implementation and operational deliverables for investigational products in a defined therapeutic area • Ensure effective cross-functional communications to align with global strategy and leads the development of clinical sections of trial and program level regulatory documents 

• Acts as the medical expert, engages interactions with external stakeholders (e.g., regulatory authorities, key opinion leaders, data monitoring committees, advisory boards etc.) and internal NVS stakeholders • Contributes to medical/scientific training of relevant Novartis stakeholders. May serve as speaker for medical/scientific training -May serve on or lead global initiatives (e.g., process improvement, training, SOP development, other Clinical Development line function initiatives)  • Experience leading early and/or late phase Oncology clinical programs from the pharma/biotech industry plus credible experience from an academic medical center. In case of no industry experience then significant academic experience with credible PI/co-PI clinical study leadership • Track record of significant contributions to your field over time, creating new concepts and seeking out new clinical discovery opportunities / approaches

Role Requirements:

Medical degree, oncology board certified preferred, and PhD level basic Science or equivalent expertise ∙ ≥ 3 years technical, operational and managerial experience in planning, executing, reporting and design of clinical trials studies in a pharmaceutical company, academic centre or contract research organisation ∙ Good knowledge of Good Clinical Practice, clinical trial design, statistics, regulatory processes, and global clinical development process ∙ Good knowledge of oncology and experience in early clinical development preferred. ∙ Good communication, writing and organization and skills, fluent in English written and spoken

Novartis is committed to building an outstanding, inclusive work environment and diverse teams' representative of the patients and communities we serve.

Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together? https://www.novartis.com/about/strategy/people-and-culture

Join our Novartis Network: Not the right Novartis role for you? Sign up to our talent community to stay connected and learn about suitable career opportunities as soon as they come up: https://talentnetwork.novartis.com/network

Benefits and Rewards: Read our handbook to learn about all the ways we’ll help you thrive personally and professionally: https://www.novartis.com/careers/benefits-rewards

Novartis is committed to building an outstanding, inclusive work environment and diverse teams' representative of the patients and communities we serve.

Epidemiology in the Division of Intramural Research

Epidemiology is a core science in public health that includes surveillance, observation, hypothesis testing, analytic research, and experiments and interventions. As the fundamental science of preventive medicine and public health, epidemiology has traditionally focused on disease causation through population studies. Epidemiologists develop and evaluate hypotheses about the effects of genetic, behavioral, environmental, and healthcare factors on human health and develop the knowledge bases for disease prevention and control programs. The field is interdisciplinary and has a methodology distinct from, but dependent on, biostatistics. Epidemiologists incorporate into their research the knowledge base and tools of other disciplines including the biologic sciences, clinical research, and other population sciences.

Main Areas of Focus

While our primary efforts focus on leading research relating to different aspects of infectious disease epidemiology and public health, epidemiologists at NIAID support research of relevance to the mission of NIAID, with approaches that include the following:

• Design of clinical and population-based studies with appropriate methods and sampling strategies, focusing on reducing study bias and improving data collection
• Analysis of randomized and non-randomized study cohorts using multivariable methods to identify host and pathogen contributions to infection and disease
• Application of machine learning and other data science tools to study disease risk factors for selected infectious diseases and immune disorders
• Molecular techniques to investigate immunological responses to emerging and re-emerging viral diseases
• Research areas of particular interest include emerging viral pathogens, antimicrobial resistance, nontuberculous mycobacteria, malaria, SARS-CoV-2, Ebola, invasive fungal infections, inborn errors of immunity

Contact Information

Leah Katzelnick, Ph.D, M.P.H. – Seroepidemiology

Jennifer Kwan, Ph.D. – Infectious disease epidemiology, geospatial statistics

Rebecca Prevots, Ph.D. – Epidemiology of nontuberculous mycobacteria

Emily Ricotta, Ph.D., M.Sc. – Infectious disease epidemiology, data management